Spyre Therapeutics, Inc.

Name: Spyre Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

SYRENasdaqCIK 1636282HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2024

Operating income−$41.6m, Q2 FY2026

Net income−$36.2m, Q2 FY2026

Spyre Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.0	0.0	0.0	0.0	0.0	0.0	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$m	(18.3)	(45.9)	(47.8)	(44.1)	(55.4)	(61.3)	(53.6)	(41.9)	(56.9)	(57.2)	(45.6)	(41.6)
Income tax	$m	0.0	0.0	0.0	0.0	0.0	0.0	(0.0)	0.0	0.0	0.0	0.0	0.0
Net income	$m	(40.1)	(63.2)	(43.9)	(38.8)	(69.0)	(56.3)	(44.8)	(36.7)	(11.2)	(62.5)	(69.0)	(36.2)
Diluted EPS	$ per share	0.86	not reported	0.72	0.59	1.06	not reported	not reported	not reported	not reported	not reported	(0.74)	not reported
Basic EPS	$ per share	0.86	not reported	0.72	0.59	1.06	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Balance sheet

Cash and equivalents$162.0m, Q2 FY2026

Shareholders' equity$1.10bn, Q2 FY2026

Spyre Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	90.6	189	228	45.1	71.6	89.4	48.5	81.7	64.9	85.7	97.2	162
Current assets	$m	206	342	487	436	421	608	570	539	505	778	764	1,173
Total assets	$m	207	342	488	436	421	608	570	539	505	778	764	1,173
Current liabilities	$m	44.9	32.0	42.8	22.1	57.5	54.1	70.7	83.1	46.3	58.7	85.2	63.3
Total liabilities	$m	65.6	73.3	81.9	61.7	93.7	90.7	87.2	83.1	49.5	62.5	93.1	71.9
Shareholders' equity	$m	(245)	184	152	374	327	518	483	456	455	715	671	1,101

Cash flow

Operating cash flow−$69.9m, Q2 FY2026

Capital expenditure$0, Q4 FY2023

Spyre Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(34.6)	(31.0)	(28.5)	(62.2)	(29.4)	(37.2)	(41.0)	(46.6)	(37.1)	(44.6)	(57.4)	(69.9)
Capital expenditure	$m	not reported	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)50.89m, Q3 FY2024

Spyre Therapeutics, Inc., shares, quarterly
Line item	Unit	Q2 FY20212021-06-30	Q3 FY20212021-09-30	Q1 FY20222022-03-31	Q2 FY20222022-06-30	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30
Diluted shares (weighted)	m shares	65.6	65.8	66.0	82.2	3.8	3.8	3.8	4.3	36.5	45.3	50.9

Shares outstanding: 88.17m at Jul 28, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. Listed shows no prices and gives no investment advice.